vs
Side-by-side financial comparison of Lifeway Foods, Inc. (LWAY) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $55.4M, roughly 1.0× Lifeway Foods, Inc.). Lifeway Foods, Inc. runs the higher net margin — 4.6% vs -83.0%, a 87.6% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 18.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 11.4%).
Lifeway Foods is an Illinois-based health food company founded in 1986. They are a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
LWAY vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.4M | $57.3M |
| Net Profit | $2.5M | $-47.5M |
| Gross Margin | 27.8% | 91.6% |
| Operating Margin | 6.8% | -82.2% |
| Net Margin | 4.6% | -83.0% |
| Revenue YoY | 18.0% | 36.9% |
| Net Profit YoY | 1688.1% | -9.6% |
| EPS (diluted) | $0.15 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.4M | $57.3M | ||
| Q3 25 | $57.1M | $51.3M | ||
| Q2 25 | $53.9M | $48.5M | ||
| Q1 25 | $46.1M | $32.7M | ||
| Q4 24 | $46.9M | $41.8M | ||
| Q3 24 | $46.1M | $33.3M | ||
| Q2 24 | $49.2M | $29.1M | ||
| Q1 24 | $44.6M | $26.0M |
| Q4 25 | $2.5M | $-47.5M | ||
| Q3 25 | $3.5M | $-52.9M | ||
| Q2 25 | $4.2M | $-46.6M | ||
| Q1 25 | $3.5M | $-49.5M | ||
| Q4 24 | $-160.0K | $-43.3M | ||
| Q3 24 | $3.0M | $-43.6M | ||
| Q2 24 | $3.8M | $-32.3M | ||
| Q1 24 | $2.4M | $-141.4M |
| Q4 25 | 27.8% | 91.6% | ||
| Q3 25 | 28.7% | 89.3% | ||
| Q2 25 | 28.6% | 88.6% | ||
| Q1 25 | 23.9% | 88.8% | ||
| Q4 24 | 25.3% | 90.9% | ||
| Q3 24 | 25.7% | 88.5% | ||
| Q2 24 | 27.0% | 89.9% | ||
| Q1 24 | 25.8% | 89.2% |
| Q4 25 | 6.8% | -82.2% | ||
| Q3 25 | 8.8% | -102.6% | ||
| Q2 25 | 10.8% | -93.4% | ||
| Q1 25 | 3.4% | -143.7% | ||
| Q4 24 | 1.5% | -98.6% | ||
| Q3 24 | 9.1% | -132.0% | ||
| Q2 24 | 11.0% | -139.2% | ||
| Q1 24 | 8.0% | -538.7% |
| Q4 25 | 4.6% | -83.0% | ||
| Q3 25 | 6.2% | -103.1% | ||
| Q2 25 | 7.9% | -96.1% | ||
| Q1 25 | 7.7% | -151.4% | ||
| Q4 24 | -0.3% | -103.6% | ||
| Q3 24 | 6.5% | -131.2% | ||
| Q2 24 | 7.7% | -110.9% | ||
| Q1 24 | 5.4% | -544.4% |
| Q4 25 | $0.15 | $-0.73 | ||
| Q3 25 | $0.23 | $-0.82 | ||
| Q2 25 | $0.28 | $-0.75 | ||
| Q1 25 | $0.23 | $-0.81 | ||
| Q4 24 | $0.00 | $-0.71 | ||
| Q3 24 | $0.19 | $-0.73 | ||
| Q2 24 | $0.25 | $-0.55 | ||
| Q1 24 | $0.16 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.6M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $85.8M | $139.1M |
| Total Assets | $105.6M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.6M | $388.9M | ||
| Q3 25 | $23.0M | $416.1M | ||
| Q2 25 | $21.2M | $291.0M | ||
| Q1 25 | $19.4M | $314.5M | ||
| Q4 24 | $16.7M | $320.6M | ||
| Q3 24 | $20.6M | $298.4M | ||
| Q2 24 | $14.6M | $319.1M | ||
| Q1 24 | $12.0M | $201.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.5M | — |
| Q4 25 | $85.8M | $139.1M | ||
| Q3 25 | $82.8M | $148.8M | ||
| Q2 25 | $78.7M | $-11.9M | ||
| Q1 25 | $74.2M | $18.9M | ||
| Q4 24 | $71.9M | $21.7M | ||
| Q3 24 | $71.5M | $11.2M | ||
| Q2 24 | $68.0M | $39.3M | ||
| Q1 24 | $63.5M | $61.6M |
| Q4 25 | $105.6M | $480.2M | ||
| Q3 25 | $109.5M | $506.9M | ||
| Q2 25 | $98.3M | $372.7M | ||
| Q1 25 | $93.7M | $386.7M | ||
| Q4 24 | $90.5M | $392.3M | ||
| Q3 24 | $91.3M | $363.6M | ||
| Q2 24 | $84.9M | $381.8M | ||
| Q1 24 | $82.8M | $258.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $267.0K | $-25.4M |
| Free Cash FlowOCF − Capex | $-17.4M | — |
| FCF MarginFCF / Revenue | -31.5% | — |
| Capex IntensityCapex / Revenue | 31.9% | — |
| Cash ConversionOCF / Net Profit | 0.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $267.0K | $-25.4M | ||
| Q3 25 | $6.9M | $-26.6M | ||
| Q2 25 | $3.9M | $-23.3M | ||
| Q1 25 | $-150.0K | $-40.4M | ||
| Q4 24 | $-2.6M | $-18.8M | ||
| Q3 24 | $7.5M | $-25.2M | ||
| Q2 24 | $6.5M | $-29.1M | ||
| Q1 24 | $1.5M | $-40.7M |
| Q4 25 | $-17.4M | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $1.6M | — | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-3.8M | — | ||
| Q3 24 | $5.9M | — | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $-923.0K | — |
| Q4 25 | -31.5% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | -5.1% | — | ||
| Q4 24 | -8.2% | — | ||
| Q3 24 | 12.8% | — | ||
| Q2 24 | 10.4% | — | ||
| Q1 24 | -2.1% | — |
| Q4 25 | 31.9% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | 0.11× | — | ||
| Q3 25 | 1.96× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | -0.04× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.50× | — | ||
| Q2 24 | 1.73× | — | ||
| Q1 24 | 0.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LWAY
| Drinkable Kefirotherthan Pro Bugs | $47.8M | 86% |
| Cheese | $4.7M | 8% |
| Cream And Other | $1.7M | 3% |
| Other | $1.2M | 2% |
RYTM
Segment breakdown not available.
